|
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland
https://globenewswire.com/news-release/2016/10/30/884427/0/en/MediciNova-Announces-MN-166-ibudilast-ALS-Abstract-Accepted-for-Presentation-at-the-27th-International-Symposium-on-ALS-MND-in-Dublin-Ireland.html |
Medicinova (MNOV) Receives Positive CHMP Opinion on Ibudilast as ALS Treatment
Medicinova (MNOV) Receives Positive CHMP Opinion on Ibudilast as ALS Treatment
Medicinova (MNOV) Receives Positive CHMP Opinion on Ibudilast as ALS Treatment |
MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product De
MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
http://www.nasdaq.com/press-release/...20161110-00207 |
EU Panel Recommends Orphan Drug Status for Ibudilast for ALS Treatment
EU Panel Recommends Orphan Drug Status for Ibudilast for ALS Treatment
EU Panel Recommends Orphan Drug Status for ALS Therapy Ibudilast |
| All times are GMT -5. The time now is 05:53 AM. |
Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.